IMIGRAN IMIGRAN IMIGRAN IMIGRAN SUMATEC NIMIGRAN SUMAPAN SUMAPAN SUMAPAN SUMTAN SUMTAN MIGROT MIGROT MIGROT MIGROT MIGROT SUMIG SUMINAP SUMINAP SUMINAP SUMOXEN SUMOXEN SUMOXEN SUMIG PLUS

Dose: 50 mg
Single Dose: 50 (50)
Frequency: 8 hourly
Route: PO
Instructions: Should be given as early as possible after the onset of a migraine headache. If a patient does not respond to the first dose, a second dose should not be taken for the same attack.

Sumatriptan (Succinate) is the derivative of Sumatriptan. It is of Synthetic origin and belongs to Sulphonamide. It belongs to 5HT-1 agonist pharmacological group on the basis of mechanism of action and also classified in Antimigraine and Serotonin 5HT1D Receptor Agonist pharmacological group.The Molecular Weight of Sumatriptan is 413.50.

'Sumatriptan is contraindicated in conditions like Diabetes mellitus,Hypertension,Myocardial infarction,Peripheral vascular disease,Ischaemic heart disease,Cerebrovascular accident,Prinzmetal''s angina,Coronary artery disease,Hypersensitivity,Hepatic impairment.'

The severe or irreversible adverse effects of Sumatriptan, which give rise to further complications include Tachycardia, Cardiac arrhythmias, Bradycardia, AV-block, Nystagmus, Seizures, Angina, Ventricular tachycardia, Ventricular fibrillation, Sinus bradycardia, Atrial fibrillation, Ischemic colitis, Syncope, Hypertensive crises, Myocardial infarction.Sumatriptan produces potentially life-threatening effects which include Myocardial Ischemia. which are responsible for the discontinuation of Sumatriptan therapy.The signs and symptoms that are produced after the acute overdosage of Sumatriptan include Diarrhea, Dyspnea, Myalgia.The symptomatic adverse reactions produced by Sumatriptan are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Dizziness, Vertigo, Drowsiness, Fatigue, Palpitation, Pain, Irritation, Flushing, Diplopia, Nausea and vomiting, Muscle cramps, Tingling, Heaviness, Pressure or tightness in body parts, Heat sensation, Reduced vision, Flickering.

Sumatriptan is primarily indicated in conditions like Cluster headache, Migraine, Treatment of acute migraine attacks.

Sumatriptan is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholButorphanol (Tartrate)Citalopram (HBr)Dihydroergotamine (Mesylate)Due to additive pharmacologic effect coadministration of these drugs may results in coronary artery vasospasm,peripheral vascular ischemia and colonic ischemia. MajorThis combination is contraindicated if use within 24 hours.Ergotamine (Tartrate)Boh drugs acts additively thus coadministration potentiate the risk of vasospastic reaction, coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia.MajorCoadministration of these agents is considered contraindicated.Fluvoxamine (Maleate)Concomitant use of these drugs potentiate the risk of serotonin syndrome due to hyperstimulation of brain stem 5-HT1A receptor.MajorClosely monitor the sign and symptoms of serotonin syndromeFurazolidoneFurazolidone inhibit metabolic clearance and elevate plasma concnetrationn of sumatriptan result in high risk of coronary artery vasospasm,peripheral vascular ischemia and colonic ischemia.MajorThis combination should be avoided or give a gap of atleast 2 weeks before or after use of any of these drugs.IsocarboxazidIsocarboxazid increases the plasma concentration of sumatriptan by inhibiting their metabolic clearence result in increased risk of vasospastic reactions, including coronory arter yvasospasm, peripheral vascular ischemia and clonic ischemia.MajorThis combination is considered contraindicated. There should be gap of at least 14 days between stopping the isocarboxazid and initiation of sumatriptan.NaratriptanConcurrent use is not recommended.NitroglycerinSumatriptancan oppose the vasodilatory actions of nitroglycerin and may cause angina. ParoxetineThis combination may potentiate the risk of serotnin syndrome.MajorConcomitant use should be avoidede.Sertraline (HCl)Concomitant use of these drugs potentiates the risk of serotonin syndrome due to hyperstimulation of brain stem 5-HT1A receptor. MajorClosely monitor the sign and symptoms of serotonin syndromeSibutramineTranylcypromine (Sulphate)Tranylcypromine increases the plasma concentration of sumatriptan by inhibiting their metabolic clearence result in increased risk of vasospastic reactions, including coronory artery vasospasm, peripheral vascular ischemia and clonic ischemia.MajorThis combination is considered contraindicated. There should be gap of at least 14 days between stopping the tranylcypromine and initiation of sumatriptan.Vortioxetineincreases the toxicityof vortioxetineuse alternative These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Liver Function Test (LFT)

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Inj, Nsal Spray Store at room temperature, Below 30°C or in refrigerator. Do not Freeze. Protect from Sunlight and Moisture.

Sumatriptan should be used with caution in patients with any pre-existing heart disease, coronary artery disease, high blood pressure, stroke, abnormal heart rhythm, kidney disease, liver disease or if have any allergy especially to sulfa drugs. Since this may cause drowsiness, use caution while driving or engaging in activities requiring alertness, avoid alcohol because it may increase drowsiness or dizziness effects. Sumatriptan should be used during pregnancy or lactation only when clearly needed. The drug should only be used where there is a clear diagnosis of migraine. Before treating headaches in patient not previously diagnosed as migrainures, and in migrainures who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. It should be noted the migranures may be at increasd risk of certain cerebrovascular events. The drug should be used with caution in the patient with the history of epilepsy or structural brain lesions which lower their convulsion threshold. The recommended dose of sumatriptan should not be exceeded.